Use of Immune Globulin Intravenous (Human), 10% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Trial Profile

Use of Immune Globulin Intravenous (Human), 10% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Rituximab (Primary) ; Immune globulin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Jan 2018.
    • 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 May 2014 Planned End Date changed from 1 Sep 2015 to 1 Sep 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top